OPEN END TURBO LONG - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000MA88HY0

Market Closed - Börse Stuttgart 20:43:47 20/06/2024 BST
1.11 EUR +4.72% Intraday chart for OPEN END TURBO LONG - BIOMARIN PHARMACEUTICAL
Current month+296.43%
1 month+164.29%
Date Price Change
20/06/24 1.11 +4.72%
19/06/24 1.06 -4.50%
18/06/24 1.11 -7.50%
17/06/24 1.2 +12.15%
14/06/24 1.07 -1.83%

Delayed Quote Börse Stuttgart

Last update June 20, 2024 at 08:43 pm

More quotes

Static data

Product typeKnock-Out ohne Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
Issuer Morgan Stanley
WKN MA88HY
ISINDE000MA88HY0
Date issued 27/07/2021
Strike 72.96 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.47
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 4.96
Lowest since issue 0.176

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
84.71 USD
Average target price
108.1 USD
Spread / Average Target
+27.60%
Consensus